Abstract
OBJECTIVES: The coexistence of chronic rhinosinusitis (CRS) and nasal polyposis (NP) with asthma is common and impairs asthma control and quality of life. Multiple clinical trials have demonstrated dupilumab’s efficacy in patients with asthma, but real-world evidence is scarce. This analysis aimed to characterize patient-reported outcomes from a global, prospective, observational registry (RAPID; NCT04287621) of patients initiating dupilumab for asthma with and without coexisting CRS and/or NP (CRS–NP). ...
| Original language | English |
|---|---|
| Publication status | Accepted/In press - 10 Apr 2025 |
| Event | ISPOR 2025: Collaborating to Improve Healthcare Decision Making for All: Expanding HEOR Horizons - Montreal, Canada Duration: 13 May 2025 → 16 May 2025 https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-2025 |
Conference
| Conference | ISPOR 2025 |
|---|---|
| Country/Territory | Canada |
| City | Montreal |
| Period | 13/05/25 → 16/05/25 |
| Internet address |
Funding
Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT04287621. Medical writing/editorial assistance was provided by Claire Pickford, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines.
| Funders | Funder number |
|---|---|
| Sanofi-Aventis | |
| Regeneron Pharmaceuticals, Inc. |